
    
      This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled
      extension study to characterising the long term safety and tolerability of of an intravenous
      treatment regimen of anifrolumab versus placebo in subjects with moderately to severely
      active systemic lupus erythematosus who completed a Phase 3 study (D3461C00004 or
      D3461C00005) through the 52-week double-blind treatment period.
    
  